Published in Cold Spring Harb Perspect Biol on January 01, 2010
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet (2011) 8.53
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Allele-specific p53 mutant reactivation. Cancer Cell (2012) 2.51
MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol (2012) 2.41
p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34
Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Cell Cycle (2011) 2.25
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One (2013) 2.00
Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev (2013) 1.88
p53 at a glance. J Cell Sci (2010) 1.88
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol (2011) 1.72
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev (2010) 1.64
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun (2013) 1.62
Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev (2013) 1.61
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 1.46
Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev (2017) 1.39
Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression. PLoS Comput Biol (2017) 1.39
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem (2012) 1.26
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol (2012) 1.23
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene (2012) 1.22
Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. Nat Commun (2014) 1.20
p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res (2011) 1.17
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A (2012) 1.17
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell (2014) 1.10
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J (2015) 1.05
Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a potential new model for oral cancer. Int J Cancer (2011) 1.03
Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget (2013) 1.03
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res (2015) 1.03
Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res (2013) 1.02
Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res (2013) 1.02
"Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med (2015) 1.01
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets (2012) 1.01
More targets, more pathways and more clues for mutant p53. Oncogenesis (2013) 1.00
Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol (2013) 0.99
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One (2013) 0.99
NOD-Like Receptors: Master Regulators of Inflammation and Cancer. Front Immunol (2014) 0.97
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat (2014) 0.97
p53 Acetylation: Regulation and Consequences. Cancers (Basel) (2014) 0.97
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev (2015) 0.96
Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis (2014) 0.94
Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell Cycle (2014) 0.94
Protein Folding and Mechanisms of Proteostasis. Int J Mol Sci (2015) 0.93
Cutaneous field cancerization: clinical, histopathological and therapeutic aspects. An Bras Dermatol (2013) 0.91
Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle (2012) 0.91
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol (2015) 0.90
Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene (2012) 0.90
Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst (2015) 0.90
Creation and preliminary characterization of a Tp53 knockout rat. Dis Model Mech (2012) 0.90
Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proc Natl Acad Sci U S A (2013) 0.90
Interaction between the Cockayne syndrome B and p53 proteins: implications for aging. Aging (Albany NY) (2012) 0.89
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res (2013) 0.89
Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs. PLoS One (2012) 0.89
A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens. Nucleic Acids Res (2012) 0.89
Connection between Cell Phone use, p53 Gene Expression in Different Zones of Glioblastoma Multiforme and Survival Prognoses. Rare Tumors (2014) 0.89
TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutat Res (2015) 0.89
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88
Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis (2015) 0.88
Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol (2014) 0.88
DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment. Cancers (Basel) (2014) 0.88
p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS One (2011) 0.88
Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos. Cancer Metastasis Rev (2013) 0.87
The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice. Arch Toxicol (2015) 0.87
Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. PLoS One (2011) 0.87
DNA repair and aging: the impact of the p53 family. Aging (Albany NY) (2015) 0.87
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies. Cancer Res (2015) 0.86
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res (2013) 0.86
Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. J Thorac Dis (2014) 0.86
Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics (2013) 0.86
Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival. Front Endocrinol (Lausanne) (2015) 0.86
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) (2015) 0.86
Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis. Cytoskeleton (Hoboken) (2014) 0.85
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One (2013) 0.85
Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc (2012) 0.85
Four Promoters of IRF5 Respond Distinctly to Stimuli and are Affected by Autoimmune-Risk Polymorphisms. Front Immunol (2013) 0.85
Reversed-phase ion-pair liquid chromatography electrospray ionization tandem mass spectrometry for separation, sequencing and mapping of sites of base modification of isomeric oligonucleotide adducts using monolithic column. J Chromatogr A (2012) 0.85
Capsaicin mediates cell cycle arrest and apoptosis in human colon cancer cells via stabilizing and activating p53. Int J Biol Sci (2014) 0.85
The genome as a record of environmental exposure. Mutagenesis (2015) 0.85
TP53 mutation, mitochondria and cancer. Curr Opin Genet Dev (2016) 0.84
Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res (2013) 0.84
Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proc Natl Acad Sci U S A (2012) 0.84
Genetically engineered mice as experimental tools to dissect the critical events in breast cancer. Adv Cancer Res (2014) 0.84
The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc Natl Acad Sci U S A (2015) 0.83
Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A (2014) 0.83
Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigenesis. Carcinogenesis (2012) 0.83
Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med (2014) 0.83
Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells. J Cancer Prev (2013) 0.83
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Cancer heterogeneity: origins and implications for genetic association studies. Trends Genet (2012) 0.83
Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol (2015) 0.83
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Instability and decay of the primary structure of DNA. Nature (1993) 25.58
The cancer genome. Nature (2009) 23.13
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2008) 11.66
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (1991) 6.16
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (1991) 6.04
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell (2000) 5.64
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science (1996) 5.17
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol (2009) 4.84
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 4.27
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (2007) 3.01
Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene (2007) 2.96
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 2.65
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet (1993) 2.40
Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene (2001) 2.36
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
Mutational spectra of human cancer. Hum Genet (2009) 2.26
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Methylation, mutation and cancer. Bioessays (1992) 2.11
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
TP53 mutations in human skin cancers. Hum Mutat (2003) 2.07
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
Germline mutations in the TP53 gene. Cancer Surv (1995) 1.85
Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol (2002) 1.83
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene (2001) 1.57
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer (2009) 1.52
Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci U S A (1996) 1.42
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis (2007) 1.39
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem (2005) 1.37
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene (2004) 1.36
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res (2007) 1.29
Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet (2009) 1.29
TP53 status and response to chemotherapy in breast cancer. Pathobiology (2008) 1.28
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis (2003) 1.24
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer (2006) 1.24
Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene (1997) 1.24
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 1.23
The role of TP53 in Cervical carcinogenesis. Hum Mutat (2003) 1.23
Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res (2008) 1.21
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A (2004) 1.16
Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle (2006) 1.15
Mechanisms for the involvement of DNA methylation in colon carcinogenesis. Cancer Res (1996) 1.14
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res (1998) 1.13
Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene (2007) 1.13
A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res (1992) 1.10
TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet (2009) 1.10
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev (2002) 1.10
Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene (2003) 1.07
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res (2003) 1.04
MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis (2006) 1.04
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer (1999) 1.03
TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis (2005) 1.03
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet (1993) 1.01
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res (2005) 1.00
HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ (2007) 0.99
Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog (2008) 0.95
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat (2004) 0.91
Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene (1999) 0.91
A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther (2009) 0.90
Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol (2008) 0.87
Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res (2006) 0.86
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle (2011) 2.79
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett (2006) 2.37
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Genetics of lung-cancer susceptibility. Lancet Oncol (2010) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer (2006) 2.17
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol (2002) 1.96
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest (2010) 1.88
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol (2009) 1.82
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut (2010) 1.71
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett (2011) 1.62
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer (2009) 1.52
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Biospecimen reporting for improved study quality (BRISQ). J Proteome Res (2011) 1.48
Massively regulated genes: the example of TP53. J Pathol (2010) 1.46
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett (2008) 1.44
In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology (2009) 1.43
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res (2007) 1.41
Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol (2013) 1.40
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis (2007) 1.39
International efforts to develop biospecimen best practices. Cancer Epidemiol Biomarkers Prev (2010) 1.38
Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer (2011) 1.36
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer (2010) 1.35
G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis (2010) 1.34
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One (2007) 1.34
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat (2010) 1.32
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res (2007) 1.27
Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol (2010) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep (2006) 1.24
Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett (2009) 1.22
Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect (2008) 1.22
Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer (2004) 1.21
The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol (2011) 1.20
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol (2010) 1.17
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res (2006) 1.16
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A (2004) 1.16
Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A (2002) 1.16
Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle (2006) 1.15
How to become immortal: let MEFs count the ways. Aging (Albany NY) (2010) 1.14
DNA adducts and lung cancer risk: a prospective study. Cancer Res (2005) 1.14
Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene (2005) 1.13
Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. Cancer Res (2010) 1.13
Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol (2013) 1.12
Biospecimen Reporting for Improved Study Quality. Biopreserv Biobank (2011) 1.12
Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev (2005) 1.12
Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One (2011) 1.11
TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. Mutagenesis (2004) 1.11
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett (2009) 1.09
Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer (2007) 1.06
Biobanking in a fast moving world: an international perspective. J Natl Cancer Inst Monogr (2011) 1.06
Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int (2010) 1.05
Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res (2012) 1.05
MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis (2006) 1.04
p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene (2004) 1.04
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicine. Biomark Med (2010) 1.02
Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer (2011) 1.01
Increase in female liver cancer in the Gambia, West Africa: evidence from 19 years of population-based cancer registration (1988-2006). PLoS One (2011) 1.01
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J (2012) 1.01
Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One (2012) 1.01
Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev (2010) 1.00
p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett (2005) 1.00
Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics (2009) 1.00
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis (2004) 0.99
Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene (2005) 0.99
Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer (2004) 0.98
Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett (2009) 0.98
TP53 and mutations in human cancer. Acta Biochim Pol (2003) 0.98
Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate, and senescence. Antioxid Redox Signal (2011) 0.98
KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer (2010) 0.98
Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol (2008) 0.98